LONG-TERM OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY HODGKIN AND NON-HODGKIN LYMPHOMA: MULTI-CENTER EXPERINCE FROM TURKEY

In this multicenter retrospective study, we evaluated the efficiency on survival and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapse/refractory (R/R) Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A total of 110 patients with R/R HL or NHL who underwent allo-HSCT were evaluated between July 2007 and October 2022 in 7 adult stem cell transplantation centers. The primary endpoints of this study were progression-free survival (PFS), graft versus host disease-free, relapse-free survival (GRFS) and overall survival (OS) after the allo-SCT Forty-one (37.3%) of total patients were diagnosed with HL, 69 (62.7%) were NHL. The median age at the time of transplantation was 39,5 years (16-67) and 66 (60%) of them male. The mean follow-up time was 67,5±8.1 months and the rates of 5-years OS, PFS, and GRFS were 38.4%, 59.3% and 49.5% respectively. In multivariate analysis, OS was significantly impacted by both conditioning regimen type and acute GvHD degree. Myeloablative conditioning regimen and grade 3-4 acute GvHD had a statistically significant negative effect on OS (HR: 1.74, 95% CI: 1.02-2.98, p=.042, and HR: 2.03, 95% CI: 1.12-3.68, p=.019, respectively). Mismatch unrelated donor (HR: 3.91, 95% CI: 1.58-9.67, p=.003) and CMV reactivation (HR: 1.99, 95% CI: 1.11-3.58, p=.020) were statistically significant negative effect on GRFS. According to our results, PFS, OS, and GRFS are not impacted by the disease subtype. However, the transplantation results are affected by the conditioning regimens, donor type, acute GVHD status, and CMV reactivation